8-K: Biofrontera Inc. Secures Full U.S. Rights to Ameluz and RhodoLED, Announces $11 Million Private Placement

Biofrontera Inc. has acquired full U.S. rights to its key products Ameluz and RhodoLED from its former parent, funded in part by an $11 million private placement of Series C Convertible Preferred Stock.

Summary

• Biofrontera Inc. (BFRI) entered into a Strategic Transaction on June 30, 2025, to acquire all U.S. rights to Ameluz and RhodoLED from its former parent company, Biofrontera AG, and its subsidiaries.
• The previous transfer pricing model (effective February 13, 2024) is replaced by a new royalty structure: 12% on Ameluz U.S. revenue below $65.0 million, and 15% when revenue exceeds $65.0 million.
• In exchange for the U.S. rights and transfer of U.S. business costs, Biofrontera AG will receive 3,109 shares of Series D Convertible Preferred Stock, representing a 10% post-money equity stake.
• The Series D Preferred Stock is convertible into common stock and has voting rights on an as-converted basis, but these rights are subject to stockholder approval.
• To fund the Strategic Transaction and for general corporate purposes, Biofrontera Inc. entered into a private placement on June 27, 2025, to issue and sell up to 11,000 shares of Series C Convertible Preferred Stock at $1,000 per share, totaling $11.0 million.
• The Series C Preferred Offering will occur in two tranches: an Initial Closing of $8.5 million expected on July 1, 2025, and a Subsequent Closing of $2.5 million expected on or before September 30, 2025, contingent on definitive documentation for the Strategic Transaction.
• Series C Preferred Stock is convertible into common stock, with conversion and voting rights capped at 19.99% of outstanding common stock as of June 27, 2025, until stockholder approval.
• Both Series C and Series D Preferred Stock have a liquidation preference equal to the greater of three times their stated value ($3,000 per share) plus unpaid dividends, or their as-converted value, prior to stockholder approval.
• The company is obligated to file resale registration statements for the common stock issuable upon conversion of the Series C Preferred Stock within 15 days of the Initial Closing and within 3 days of the Subsequent Closing, aiming for effectiveness within 60-75 days.
• Certain purchasers, who are also holders of the company's 10.0% Senior Secured Convertible Notes Due November 22, 2027, have consented to these transactions, waiving potential breaches of their note covenants.

Sentiment

Score: 6

Explanation: The strategic acquisition of full U.S. rights to key products is a positive step for long-term control and potential revenue growth. However, the financing structure involves significant potential dilution from preferred stock with a high liquidation preference (3X stated value), which could be detrimental to common shareholders in certain scenarios. The capital raise itself addresses funding needs but comes with terms that favor new investors. The overall sentiment is cautiously positive, acknowledging the strategic benefit but highlighting the financial implications for existing common shareholders.

Positives

• Acquisition of full U.S. rights to Ameluz and RhodoLED provides Biofrontera Inc. with direct control over its key products in a significant market, potentially streamlining operations and strategy.
• The new royalty structure replaces a transfer pricing model, which could offer more predictable cost structures and potentially higher net revenue share for the company if Ameluz revenue grows significantly beyond $65.0 million.
• The capital raise of $11.0 million provides funding for the acquisition and transfer costs of the strategic transaction, as well as general corporate purposes, enhancing liquidity.
• The consent from existing noteholders for these transactions and the Strategic Transaction avoids potential defaults or disputes related to prior debt covenants.

Negatives

• The issuance of Series C and Series D Convertible Preferred Stock introduces significant potential dilution for existing common stockholders upon conversion.
• The Series C and Series D Preferred Stock carry a substantial liquidation preference of three times their stated value ($3,000 per share) prior to stockholder approval, which could significantly impact common stockholders in a liquidation event.
• The preferred stock conversion and voting rights are capped at 19.99% until stockholder approval, which could limit the influence of new preferred stockholders initially but also indicates a need for future shareholder votes.
• The new royalty payment of 12% or 15% on Ameluz U.S. revenue represents an ongoing cost to the company, replacing a prior arrangement.

Risks

• The effectiveness of the Series C and Series D Preferred Stock conversion and voting rights is contingent on obtaining Stockholder Approval, which is not guaranteed and requires a proxy statement filing and shareholder vote.
• Failure to obtain Stockholder Approval could impact the rights of preferred stockholders and potentially trigger other issues related to Nasdaq listing rules.
• The company is required to file resale registration statements for the common stock issuable upon conversion of the Series C Preferred Stock within specific deadlines, and failure to meet these could result in late registration payments (1% of aggregate Preferred Share Purchase Price every 30 days).
• The Series C and Series D Preferred Stock are not registered under the Securities Act and have no established public trading market, limiting liquidity for these specific securities.
• The company's ability to file other registration statements is restricted until all Registrable Shares are registered and effective, potentially limiting future capital raising flexibility.

Future Outlook

Biofrontera Inc. aims to gain full control over its key U.S. assets, Ameluz and RhodoLED, which is expected to streamline operations and potentially enhance future revenue capture through a new royalty structure. The company plans to use the proceeds from the Series C Preferred Offering to cover acquisition and transfer costs and for general corporate purposes, indicating a focus on integrating the newly acquired rights and supporting ongoing business. Future actions include obtaining stockholder approval for the preferred stock issuances and ensuring timely registration for resale of the common stock issuable upon conversion.

Management Comments

• The company's Board of Directors shall unanimously recommend that the Proposal (stockholder approval for preferred stock issuance) be approved by the stockholders at all meetings where it is considered.
• The company will modify its dividend policy to consider in good faith the issuance of dividends or share buybacks from annual net cash flow, subject to existing debt covenants.

Industry Context

This strategic transaction positions Biofrontera Inc. to have complete control over its flagship products, Ameluz (a photodynamic therapy for actinic keratosis) and RhodoLED (a medical device), within the crucial U.S. market. This move is common in the pharmaceutical and medical device industries where companies seek to consolidate intellectual property and commercial rights to maximize market penetration and profitability. By acquiring full U.S. rights, Biofrontera Inc. can directly manage its commercial strategy, marketing, and distribution, potentially leading to more agile market responses and direct benefit from sales growth, rather than relying on a transfer pricing model with a former parent company. This could enhance its competitive standing against other dermatology and photodynamic therapy providers in the U.S.

Comparison to Industry Standards

• The 3X liquidation preference for the Series C and Series D Preferred Stock is a high multiple, often seen in distressed financing or early-stage ventures where investors demand significant downside protection. For a publicly traded company, this indicates a strong preference for the new investors over common shareholders in a liquidation scenario, which could be viewed unfavorably by the market.
• The 19.99% beneficial ownership cap on conversion and voting rights for preferred stock until shareholder approval is a standard mechanism used by public companies to comply with Nasdaq listing rules (specifically Rule 5635, which requires shareholder approval for issuances exceeding 20% of outstanding common stock or voting power). This is a common workaround to avoid immediate shareholder votes for private placements.
• The royalty structure (12-15% of Ameluz U.S. revenue) is a common model for licensing agreements in the pharmaceutical industry. The specific rates would need to be compared to similar product licensing deals in dermatology to assess their competitiveness, but without specific comparables, it's difficult to definitively assess if it's above or below industry standards.
• The requirement to file a resale registration statement within 15 days (Initial Closing) and 3 days (Subsequent Closing) and achieve effectiveness within 60-75 days is a typical timeline for such transactions, reflecting standard regulatory expectations for liquidity for private placement investors.

Corporate Governance

Related Party Transactions

• The Strategic Transaction involves Biofrontera Inc. acquiring U.S. rights from its former parent company, Biofrontera AG, and its subsidiaries. As part of the consideration, Biofrontera AG will receive 3,109 shares of Series D Convertible Preferred Stock, representing a 10% post-money equity stake in Biofrontera Inc.

Stakeholder Impact

• **Shareholders (Common Stockholders)**: Face potential dilution from the conversion of Series C and Series D Preferred Stock. The preferred stock's 3X liquidation preference significantly subordinates common stock in a liquidation event. Shareholder approval is required for full conversion and voting rights of the preferred stock, giving common shareholders a say in the ultimate impact.
• **New Preferred Stock Investors (Series C & D)**: Gain significant rights, including a high liquidation preference and conversion rights into common stock. They also receive registration rights for the common stock, providing a path to liquidity.
• **Biofrontera AG (Former Parent)**: Receives a 10% post-money equity stake in Biofrontera Inc. and will receive ongoing royalties on Ameluz U.S. revenue, maintaining a financial interest in the product's success while transferring U.S. business costs.
• **Creditors (Noteholders)**: Certain purchasers who are also holders of the 10.0% Senior Secured Convertible Notes have consented to these transactions, indicating their approval and waiving potential covenant breaches, which is positive for the company's debt standing.

Next Steps

• Initial Closing of the Series C Preferred Offering is expected on July 1, 2025.
• The company will file a resale registration statement for the common stock issuable from the initial Series C shares within 15 days of the Initial Closing.
• The company will use commercially reasonable efforts to have the initial resale registration statement declared effective within 60 days (or 75-90 days if SEC reviews).
• Definitive documentation for the Strategic Transaction is expected to occur on or before September 30, 2025.
• Subsequent Closing of the Series C Preferred Offering is expected on or before September 30, 2025, after definitive documentation for the Strategic Transaction.
• The company will file a resale registration statement for the common stock issuable from the subsequent Series C shares as soon as practicable after the Subsequent Closing (no later than 3 days thereafter).
• The company will use commercially reasonable efforts to have the subsequent resale registration statement declared effective within 60 days (or 75-90 days if SEC reviews).
• The company will file a preliminary proxy statement for stockholder approval of the Series C and Series D Preferred Stock issuance and conversion shares within 30 days of June 30, 2025.
• The company will file and mail a definitive proxy statement for stockholder approval as soon as practicable after SEC review.
• If stockholder approval is not obtained at the first meeting, the company will resubmit the proposal semi-annually until approval is obtained.
• The company will modify its dividend policy to consider dividends or share buybacks from annual net cash flow.

Key Dates

Recommendation

Keywords

Biofrontera Inc., Ameluz, RhodoLED, SEC Filing, 8-K, Strategic Transaction, Private Placement, Convertible Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Capital Raise, Royalty Agreement, U.S. Rights, Nasdaq Listing Rules, Stockholder Approval, Dilution, Liquidation Preference, Financial Reporting, Pharmaceuticals, Dermatology